Foxx Development Holdings Inc. (NASDAQ:FOXX) Short Interest Update

Foxx Development Holdings Inc. (NASDAQ:FOXX) was the target of a large drop in short interest during the month of January. As of January 15th, there was short interest totaling 67,690 shares, a drop of 21.7% from the December 31st total of 86,407 shares. Based on an average daily volume of 16,377 shares, the short-interest ratio is presently 4.1 days. Currently, 1.5% of the company’s stock are short sold. Currently, 1.5% of the company’s stock are short sold. Based on an average daily volume of 16,377 shares, the short-interest ratio is presently 4.1 days.

Foxx Development Stock Performance

Shares of NASDAQ FOXX traded up $0.35 during midday trading on Friday, hitting $4.47. 7,807 shares of the company’s stock traded hands, compared to its average volume of 15,241. Foxx Development has a 1 year low of $1.71 and a 1 year high of $8.88. The stock has a market capitalization of $30.31 million, a price-to-earnings ratio of -3.10 and a beta of -0.21. The firm has a fifty day moving average of $4.50 and a 200 day moving average of $4.87.

Foxx Development (NASDAQ:FOXX) last issued its quarterly earnings results on Tuesday, November 18th. The company reported ($0.42) earnings per share for the quarter. The firm had revenue of $20.22 million for the quarter.

Institutional Investors Weigh In On Foxx Development

An institutional investor recently raised its position in Foxx Development stock. JPMorgan Chase & Co. lifted its position in shares of Foxx Development Holdings Inc. (NASDAQ:FOXX) by 170.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,947 shares of the company’s stock after buying an additional 3,121 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.07% of Foxx Development worth $27,000 at the end of the most recent quarter. 60.44% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Foxx Development in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Foxx Development currently has an average rating of “Sell”.

Foxx Development Company Profile

Foxx Development, Inc (NASDAQ: FOXX) operates as a contract manufacturer specializing in the design, assembly and distribution of medical devices and components. The company’s core business centers on phlebotomy and blood collection products, serving clinical laboratories, hospitals and diagnostic testing facilities. Its product portfolio includes evacuated blood collection tubes, safety-engineered winged blood collection sets, syringes and ancillary devices used in specimen collection and handling.

Founded in North Carolina, Foxx Development maintains a manufacturing and distribution campus in Apex, where it integrates engineering, quality control and regulatory compliance under one roof.